Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody

• Published in: PloS one 2015-02, Vol.10 (2), p.e0118096-e0118096
• Main Authors: Jobsri, Jantipa, Allen, Alex, Rajagopal, Deepa, Shipton, Michael, Kanyuka, Kostya, Lomonossoff, George P, Ottensmeier, Christian, Diebold, Sandra S, Stevenson, Freda K, Savelyeva, Natalia
• Format: Article
• Language: English
• Subjects: Alum; Aluminum sulfate; Analysis; Animals; Antibodies; Antibodies, Viral - immunology; Antigens; B cells; Cancer; Cancer vaccines; Cell activation; Chemokines; Cytokines; Dendritic Cells; Design; Female; Health aspects; Immune system; Immunoglobulin G; Immunoglobulin G - immunology; Immunoglobulins; Inflammation; Interleukin 12; Interleukin-12 - metabolism; Lymphatic system; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Male; Malignancy; Medicine; Mice; Mice, Inbred C57BL; Molecular chains; Nicotiana - virology; Peptides; Plant viruses; Plant Viruses - immunology; Proteins; Spleen; T cell receptors; T cells; TLR7 protein; Toll-Like Receptor 7 - genetics; Toll-Like Receptor 7 - metabolism; Toll-like receptors; Tumors; Vaccines; Virion - immunology; Virus-like particles; Viruses; α-Interferon
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0118096

Induction of potent antibody is the goal of many vaccines targeted against infections or cancer. Modern vaccine designs that use virus-like particles (VLP) have shown efficacy for prophylactic vaccination against virus-associated cancer in the clinic. Here we used plant viral particles (PVP), which are structurally analogous to VLP, coupled to a weak idiotypic (Id) tumour antigen, as a conjugate vaccine to induce antibody against a murine B-cell malignancy. The Id-PVP vaccine incorporates a natural adjuvant, the viral ssRNA, which acts via TLR7. It induced potent protective anti-Id antibody responses in an in vivo mouse model, superior to the "gold standard" Id vaccine, with prevalence of the IgG2a isotype. Combination with alum further increased antibody levels and maintained the IgG2a bias. Engagement of TLR7 in vivo was followed by secretion of IFN-α by plasmacytoid dendritic cells and by activation of splenic CD11chi conventional dendritic cells. The latter was apparent from up-regulation of co-stimulatory molecules and from secretion of a wide range of inflammatory cytokines and chemokines including the Th1-governing cytokine IL-12, in keeping with the IgG2a antibody isotype distribution. PVP conjugates are a novel cancer vaccine design, offering an attractive molecular form, similar to VLP, and providing T-cell help. In contrast to VLP, they also incorporate a safe "in-built" ssRNA adjuvant.